Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gene selection study for prognosis and prediction in advanced or relapsed colorectal cancer treated with first-line FOLFIRI
ChiCTR-TNC-11001535Phase 4Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of irinotecan and fluorouracil in colorectal cancer (CRC), sponsored by Henan Cancer Hospital. Primary endpoints: SNPs associated with efficacy and side effects of irinotecan and fluorouracil, Grade III/IV diarrhea, neutropenia, and/or leukopenia incidence and toxicity-related TTF and 2 more. Started Aug 2011; status: recruiting.
02
Drugs
irinotecanfluorouracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR-TNC-11001535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TNC-11001535.